Table 1 Clinical and biological data from the 48 patients included in the microarray analysis

Number of patients

10

16

18

4

48

Pre-treatment risk group

  Very low + low

10

2

0

3

15

  Intermediate

0

10

2

0

12

  High

0

4

16

1

21

Age at diagnostic in months

  Median

11.1

18.6

27.6

4

16.1

  Range

1.5-22.7

4.8-109.3

6.6-79.8

1.9-6.7

1.5-109.3

Patients over 18 months at diagnostic

4

9

11

0

24

Sex

  Female

6

8

6

2

22

  Male

4

8

12

2

26

Primary site

  Adrenal

1

5

9

3

18

  Abdominal

4

5

2

0

11

  Cervical

0

1

0

1

2

  Thoracic

2

0

4

0

6

  Cervical-thoracic

0

1

0

0

1

  Thoracic-abdominal

1

1

0

0

2

  Pelvic

1

0

0

0

1

  Other sites

1

3

3

0

7

Protocol of treatment

  LNESG I

2

0

0

0

2

  LNESG II

1

0

0

0

1

  EUNS

0

2

0

0

2

  INES

3

5

2

2

12

  HR-NBL-1

0

4

9

0

13

  Other (national protocols)

4

4

7

2

17

MYCN status

  Amplified (%)

0 (0%)

4 (25%)

8 (44%)

1 (25%)

13 (27%)

  Not amplified (%)

10 (100%)

12 (75%)

10 (56%)

3 (75%)

35 (73)

1p status

  Normal (%)

8 (80%)

8 (50%)

8 (44%)

3 (75%)

27 (56%)

  Deleted (%)

0 (0%)

4 (25%)

7 (39%)

0 (0%)

11 (23%)

  Not determined (%)

2 (20%)

4 (25%)

3 (17%)

1 (25%)

10 (21%)

Patients with relapse (%)

1 (10%)

7 (44%)

11 (61%)

1 (25%)

20 (42%)

Type of relapse

  Local

1

5

2

0

8

  Metastatic

0

1

3

1

5

  Local + metastatic

0

1

6

0

7

Dead (%)

0 (0%)

5 (32%)

12 (67%)

1 (25%)

18 (38%)

Cause of death

  Disease progression

0

4

11

1

16

  Other

0

1

1

0

2

Time of follow-up (month)

  Median

152.1

93.5

45.4

129.3

117.4

  Range

87.8-208.3

9.4-206.5

3.4-161.2

17.2-214.9

3.4-214.9